// App-Quantinova.ai

OP0180 (2022) : EFFECT OF AVACOPAN ON RELAPSE RATES AND RELAPSE-FREE TIME IN PATIENTS WITH ANCA-ASSOCIATED VASCULITIS, RESULTS OF THE PHASE 3 ADVOCATE STUDY

Researchers

Presenter

  • P. A. Merkel

Principal Investigators

  • H. Yue

  • E. deGoma

  • P. Bekker

  • D. Jayne

Medical Centers

  • University of Pennsylvania, Division of Rheumatology, Philadelphia, United States of America

  • Chemocentryx, Clinical Development, San Carlos, United States of America

  • University of Cambridge, Department of Oncology, Cambridge, United Kingdom

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Autoimmune (AI)

Disease

  • Anti-neutrophil cytoplasmic antibody-associated vasculitis

Biomarkers

  • N/A

Drug/Treatment

  • Prednisone

  • CCX-168

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved